Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurofibromatosis Type 1

Interventions

DRUG: Selumetinib granule formulation
DRUG: Selumetinib capsule formulation

Sponsor

AstraZeneca

Collaborators

[object Object]